137 related articles for article (PubMed ID: 28222333)
1. Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges.
Bethmann D; Feng Z; Fox BA
Curr Opin Immunol; 2017 Apr; 45():60-72. PubMed ID: 28222333
[TBL] [Abstract][Full Text] [Related]
2. The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.
Öjlert ÅK; Halvorsen AR; Nebdal D; Lund-Iversen M; Solberg S; Brustugun OT; Lingjaerde OC; Helland Å
Mol Oncol; 2019 May; 13(5):1166-1179. PubMed ID: 30854794
[TBL] [Abstract][Full Text] [Related]
3. Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells.
Yang YQ; Dong WJ; Yin XF; Xu YN; Yang Y; Wang JJ; Yuan SJ; Xiao J; DeLong JH; Chu L; Xu HN; Zhou XM; Wang RW; Fang L; Liu XY; Zhang KJ
Protein Cell; 2016 Jul; 7(7):538-43. PubMed ID: 27295261
[No Abstract] [Full Text] [Related]
4. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
5. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
[TBL] [Abstract][Full Text] [Related]
6. Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses.
Zhang Y; Morgan R; Chen C; Cai Y; Clark E; Khan WN; Shin SU; Cho HM; Al Bayati A; Pimentel A; Rosenblatt JD
Int Immunol; 2016 Sep; 28(9):423-33. PubMed ID: 26895637
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody 14C5 targets integrin alphavbeta5.
Burvenich I; Schoonooghe S; Vervoort L; Dumolyn C; Coene E; Vanwalleghem L; Van Huysse J; Praet M; Cuvelier C; Mertens N; De Vos F; Slegers G
Mol Cancer Ther; 2008 Dec; 7(12):3771-9. PubMed ID: 19074852
[TBL] [Abstract][Full Text] [Related]
8. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
[TBL] [Abstract][Full Text] [Related]
9. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
11. TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer.
Bianchi F; Alexiadis S; Camisaschi C; Truini M; Centonze G; Milione M; Balsari A; Tagliabue E; Sfondrini L
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093313
[TBL] [Abstract][Full Text] [Related]
12. The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.
Perea F; Bernal M; Sánchez-Palencia A; Carretero J; Torres C; Bayarri C; Gómez-Morales M; Garrido F; Ruiz-Cabello F
Int J Cancer; 2017 Feb; 140(4):888-899. PubMed ID: 27785783
[TBL] [Abstract][Full Text] [Related]
13. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
14. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
Passiglia F; Bronte G; Bazan V; Natoli C; Rizzo S; Galvano A; Listì A; Cicero G; Rolfo C; Santini D; Russo A
Oncotarget; 2016 Apr; 7(15):19738-47. PubMed ID: 26918451
[TBL] [Abstract][Full Text] [Related]
16. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
[TBL] [Abstract][Full Text] [Related]
17. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
Tyagi P; Mirakhur B
Clin Lung Cancer; 2009 Sep; 10(5):371-4. PubMed ID: 19808198
[TBL] [Abstract][Full Text] [Related]
18. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
[TBL] [Abstract][Full Text] [Related]
19. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
20. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy].
Kayser G
Pathologe; 2015 Nov; 36 Suppl 2():189-93. PubMed ID: 26391246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
